Negative relationship between morphine analgesia and P-glycoprotein expression levels in the brain

Journal of Pharmacological Sciences

Volumn 105, Issue 4, 2007, Pages 353-360

  Hamabe, Wakako ^a,b   Maeda, Takehiko ^a   Kiguchi, Norikazu ^a   Yamamoto, Chizuko ^a   Tokuyama, Shogo ^b   Kishioka, Shiroh ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

Analgesia; Blood brain barrier; Individual difference; Morphine; P glycoprotein

Indexed keywords

ADENOSINE TRIPHOSPHATASE; GLYCOPROTEIN P; MORPHINE;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; CELL MEMBRANE; CONTROLLED STUDY; DRUG TRANSPORT; ENZYME ACTIVITY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

EID: 37549009929     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0071287     Document Type: Article

References (33)

1. Mogil JS. The genetic mediation of individual differences in sensitivity to pain and its inhibition. Proc Natl Acad Sci U S A. 1999;96:7744-7751.
2. Ishikawa T, Hirano H, Onishi Y, Sakurai A, Tarui S. Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: highspeed screening and structure-activity relationship analyses. Drug Metab Pharmacokinet. 2004;9:1-14.
3. Mogil JS, Sternberg WF, Marek P, Sadowski B, Belknap JK, Liebeskind JC. The genetics of pain and pain inhibition. Proc Natl Acad Sci U S A. 1996;93:3048-3055.
4. Klepstad P, Dale O, Skorpen F, Borchgrevink PC, Kaasa S. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand. 2005;49:902-908.
5. Ohtsuki S, Hori S, Terasaki T. [Molecular mechanisms of drug influx and efflux transport at the blood-brain barrier]. Folia Pharmacol Jpn. (Nippon Yakurigaku Zasshi). 2003;122:55-64. (text in Japanese with English abstract)
6. Tunblad K, Ederoth P, Gardenfors A, Hammarlund-Udenaes M, Nordstrom CH. Altered brain exposure of morphine in experimental meningitis studied with microdialysis. Acta Anaesthesiol Scand. 2004;48:294-301.
7. Tsuji A, Sakata A, Tamai I. [Tissue distribution of the multidrug-resistance gene product P-glycoprotein and its physiological function]. Nippon Rinsho. 1997;55:1059-1063. (text in Japanese with English abstract)
8. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006;234:4-33.
9. Kamei J, Hirano S, Miyata S, Saitoh A, Onodera K. Effects of first- and second-generation histamine-H1-receptor antagonists on the pentobarbital-induced loss of the righting reflex in streptozotocin-induced diabetic mice. J Pharmacol Sci. 2005;97:266-272.
10. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999;39:361-398.
11. Hamabe W, Maeda T, Fukazawa Y, Kumamoto K, Shang LQ, Yamamoto A, et al. P-glycoprotein ATPase activating effect of opioid analgesics and their P-glycoprotein-dependent antinociception in mice. Pharmacol Biochem Behav. 2006;85:629-636.
12. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther. 2001;297:1137-1143.
13. Meineke I, Freudenthaler S, Hofmann U, Schaeffeler E, Mikus G, Schwab M, et al. Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br J Clin Pharmacol. 2002;54:592-603.
14. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, et al. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol. 2002;13:1847-1854.
15. Takagi H, Inukai T, Nakama M. A modification of Haffner's method for testing analgesics. Jpn J Pharmacol. 1966;16:287-294.
16. Boado RJ, Pardridge MM. A one-step procedure for isolation of poly(A)+ mRNA from isolated brain capillaries and endothelial cells in culture. J Neurochem. 1991;57:2136-2139.
17. Dallaire L, Tremblay L, Beliveau R. Purification and characterization of metabolically active capillaries of the blood-brain barrier. Biochem J. 1991;276:745-752.
18. He L, Liu GQ. Interaction of multidrug resistance reversal agents with P-glycoprotein ATPase activity on blood-brain barrier. Acta Pharmacol Sin. 2002;23:423-429.
19. Garrigos M, Mir LM, Orlowski S. Competitive and noncompetitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase - further experimental evidence for a multisite model. Eur J Biochem. 1997;244:664-673.
20. Karakucuk EH, Yamanoglu T, Demirel O, Bora N, Zengil H. Temporal variation in drug interaction between lithium and morphine-induced analgesia. Chronobiol Int. 2006;23:675-682.
21. Weed MR, Hienz RD. Effects of morphine on circadian rhythms of motor activity and body temperature in pig-tailed macaques. Pharmacol Biochem Behav. 2006;84:487-496.
22. Al-Shawi MK, Polar MK, Omote H, Figler RA. Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein. J Biol Chem. 2003;278:52629-52640.
23. Kest B, Wilson SG, Mogil JS. Sex differences in supraspinal morphine analgesia are dependent on genotype. J Pharmacol Exp Ther. 1999;289:1370-1375.
24. Wilson SG, Bryant CD, Lariviere WR, Olsen MS, Giles BE, Chesler EJ, et al. The heritability of antinociception II: pharmacogenetic mediation of three over-the-counter analgesics in mice. J Pharmacol Exp Ther. 2003;305:755-764.
25. Kalinichev M, White DA, Holtzman SG. Individual differences in locomotor reactivity to a novel environment and sensitivity to opioid drugs in the rat. I. Expression of morphine-induced locomotor sensitization. Psychopharmacology (Berl). 2004;177:61-67.
26. White DA, Kalinichev M, Holtzman SG. Individual differences in locomotor reactivity to a novel environment and sensitivity to opioid drugs in the rat. II. Agonist-induced antinociception and antagonist-induced suppression of fluid consumption. Psychopharmacology (Berl). 2004;177:68-78.
27. Macintyre PE, Jarvis DA. Age is the best predictor of postoperative morphine requirements. Pain. 1996;64:357-364.
28. Thirlwell MP, Sloan PA, Maroun JA, Boos GJ, Besner JG, Stewart JH, et al. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer. 1989;63:2275-2283.
29. Glare PA, Walsh TD. Clinical pharmacokinetics of morphine. Ther Drug Monit. 1991;13:1-23.
30. Shafer SL, Varvel JR. Pharmacokinetics, pharmacodynamics, and rational opioid selection. Anesthesiology. 1991;74:53-63.
31. Collin E, Poulain P, Gauvain-Piquard A, Petit G, Pichard-Leandri E. Is disease progression the major factor in morphine 'tolerance' in cancer pain treatment? Pain. 1993;55:319-326.
32. Mogil JS, Kest B, Sadowski B, Belknap JK. Differential genetic mediation of sensitivity to morphine in genetic models of opiate antinociception: influence of nociceptive assay. J Pharmacol Exp Ther. 1996;276:532-544.
33. Bouw R, Ederoth P, Lundberg J, Ungerstedt U, Nordstrom CH, Hammarlund-Udenaes M. Increased blood-brain barrier permeability of morphine in a patient with severe brain lesions as determined by microdialysis. Acta Anaesthesiol Scand. 2001;45:390-392.